Position papers 2013
Deutschland (BIO Deutschland), calls for the introduction of a grace period with the following key elements: Duration: 12 months Scope: Any prior disclosure of an invention does…
BIO Deutschland, the German Biotech Association, representing research-based biotech SMEs, welcomes the opportunity to submit comments on the draft ‘Policy 0070 on publication and access to clinical-trial data’.
BIO Deutschland calls for the continued, long-term improvement of scientific excellence. The following measures should be implemented as a matter of urgency: The private sector should be given priority: taxpayers’ money should not be misused to subsidise services provided by academic research in a way that threatens the competitiveness of industrial service suppliers and thus puts jobs at risk.